SCHEMBL892910

SCHEMBL892910

O=C([O-])CC(CC(F)(F)C(F)(F)C(F)(F)C(F)F)(C(=O)OCC(F)(F)C(F)(F)C(F)(F)C(F)F)S(=O)(=O)O.[Na+]

nearest known ligand 0.30

Known targets — ChEMBL curated mechanism

ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.30
MAPT P10636 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL893127 0.88 USP2 (0.31) USP2MAPTTSHR
SCHEMBL6725199 0.84 CA4 (0.30)
SCHEMBL6063777 0.75
SCHEMBL5385256 0.73 USP2 (0.33) USP2MAPTTSHR
SCHEMBL7513032 0.71 ALDH1A1 (0.32)
SCHEMBL4614918 0.69 RECQL (0.41) TSHR
SCHEMBL27628647 0.69 TSHR (0.35) USP2MAPTTSHR
SCHEMBL5946667 0.68 CA4 (0.34) TSHR
SCHEMBL12076820 0.67 TSHR (0.42) USP2MAPTTSHR
SCHEMBL12646616 0.67 TSHR (0.38) USP2MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084367-B2 Etching, cleaning and drying methods using supercritical fluid and chamber systems using these methods SAMSUNG ELECTRONICS CO., LTD (KR) 2011-12-27 US claimed
US-20070293054-A1 ETCHING, CLEANING AND DRYING METHODS USING SUPERCRITICAL FLUID AND CHAMBER SYSTEMS USING THESE METHODS SAMSUNG ELECTRONICS CO., LTD. 2007-12-20 US claimed
US-7002044-B2 Catalysis by water-soluble organometallic complexes in water-in-densified fluid microemulsions THE UNIVERSITY OF CONNECTICUT (US) 2006-02-21 US claimed
US-20040097761-A1 Catalysis by water-soluble organometallic complexes in water-in-densified fluid microemulsions CONNECTICUT, THE UNIVERSITY OF 2004-05-20 US claimed
US-10155903-B2 Metal etchant compositions and methods of fabricating a semiconductor device using the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2018-12-18 US disclosed
US-20160204001-A1 METAL ETCHANT COMPOSITIONS AND METHODS OF FABRICATING A SEMICONDUCTOR DEVICE USING THE SAME LEE HYOSAN (KR) 2016-07-14 US disclosed
US-20150368557-A1 METAL ETCHANT COMPOSITIONS AND METHODS OF FABRICATING A SEMICONDUCTOR DEVICE USING THE SAME CORNELL UNIVERSITY 2015-12-24 US disclosed
US-8951383-B2 Apparatus for treating wafers using supercritical fluid SAMSUNG ELECTRONICS CO., LTD. (KR) 2015-02-10 US disclosed
US-8790470-B2 Etching, cleaning and drying methods using supercritical fluid and chamber systems using these methods SAMSUNG ELECTRONICS CO., LTD. (KR) 2014-07-29 US disclosed
US-8585917-B2 Etching, cleaning and drying methods using supercritical fluid and chamber systems using these methods SAMSUNG ELECTRONICS CO., LTD. (KR) 2013-11-19 US disclosed
US-20120085495-A1 ETCHING, CLEANING AND DRYING METHODS USING SUPERCRITICAL FLUID AND CHAMBER SYSTEMS USING THESE METHODS LEE HYO-SAN (US) 2012-04-12 US disclosed
US-20120080059-A1 ETCHING, CLEANING AND DRYING METHODS USING SUPERCRITICAL FLUID AND CHAMBER SYSTEMS USING THESE METHODS LEE HYO-SAN (US) 2012-04-05 US disclosed
US-8084367-B2 Etching, cleaning and drying methods using supercritical fluid and chamber systems using these methods SAMSUNG ELECTRONICS CO., LTD (KR) 2011-12-27 US disclosed
US-20110083807-A1 Apparatus for Treating Wafers Using Supercritical Fluid CARESTREAM HEALTH, INC. 2011-04-14 US disclosed
US-20070293054-A1 ETCHING, CLEANING AND DRYING METHODS USING SUPERCRITICAL FLUID AND CHAMBER SYSTEMS USING THESE METHODS SAMSUNG ELECTRONICS CO., LTD. 2007-12-20 US disclosed
US-7002044-B2 Catalysis by water-soluble organometallic complexes in water-in-densified fluid microemulsions THE UNIVERSITY OF CONNECTICUT (US) 2006-02-21 US disclosed
US-20040097761-A1 Catalysis by water-soluble organometallic complexes in water-in-densified fluid microemulsions CONNECTICUT, THE UNIVERSITY OF 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097761-A1 Catalysis by water-soluble organometallic complexes in water-in-densified fluid microemulsions MGAM, NSFL1C, LIPA USP2 1727/4885MAPT 2250/4885TSHR 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.